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NMO in pediatric patients
Brain involvement and clinical expression
Joaquín A. Peña1, María Elena Ravelo2,
Eduardo Mora-La Cruz3, Cecilia Montiel-Nava4
ABSTRACT
Objective: To analyze the clinical, neuroimaging characteristics and positivity of the
acquaporin water channel (NMO-IgG) in pediatric patients with neuromyelitis optica (NMO).
This disorder could have a variable clinical expression. To address such variability, the
term NMO spectrum has been suggested. Method: We evaluated six pediatric patients,
with a median age of 11 years at the time of the study, with the diagnosis of NMO by
the Wingerchuck criteria. Results: All the cases exhibited bilateral optic neuritis (ON).
Four patients had abnormalities on brain MRI from the onset,although only three of them
developed symptoms correlated to those lesions during the course of their disorder. NMOIgG was positive in 80%. Conclusion: Optic neuropathy is the most impaired feature in
NMO patients. Brain MRI lesions are not compatible with multiple sclerosis and positivity
of the NMO-IgG are also present in NMO pediatric patients, confirming the heterogeneity
in the expression of this disorder.
Key words: neuromyelitis optica, multiple sclerosis, optic neuritis, transverse myelitis,
pediatric patients.
NMO en pacientes pediátricos: afectación del cerebro y expresión clínica
RESUMEN
Objetivo: Analizar las características clínicas y de neuroimagen, y la positividad del canal de
agua acuaporin (NMO-IgG) en pacientes pediátricos con neuromielitis óptica (NMO). Este
trastorno puede tener una expresión clínica variable. El término espectro de NMO ha sido
propuesto para poder incluir la variabilidad. Metodo: Evaluamos seis pacientes pediátricos,
con una mediana de edad de 11 años al momento del estudio, con el diagnóstico de
NMO de acuerdo a los criterios de Wingerchuck. Resultados: Todos los casos exhibían
neuritis óptica bilateral (ON). Cuatro pacientes tuvieron anormalidades en la RM cerebral
desde el inicio, aunque solo tres de ellos desarrollaron síntomas relacionados con las
lesiones durante el curso de la enfermedad. NMO-IgG fue positiva en el 80%. Conclusión:
Neuropatía óptica es la característica mayormente observada en los pacientes con NMO.
Lesiones cerebrales en la RM cerebral no compatibles con esclerosis multiple y positividad
de la NMO-IgG están también presentes en los pacientes pediátricos con NMO; lo cual
confirma la heterogeneidad en la expresión clínica de este trastorno.
Palabras-claves: neuromielitis óptica, esclerosis múltiple, neuritis óptica, myelitis transversa,
pacientes pediátricos.
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Neuromyelitis optica (NMO) is an uncommon inflammatory demyelinating
disorder characterized by severe acute
transverse myelitis (TM) with bilateral
simultaneous or sequential optic neuri1

tis (ON). Usually reported in adults and
rarely in children, NMO has been considered an exceptional manifestation of multiple sclerosis (MS)1-5. However, it seems to
be a distinct entity with different underly-
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ing pathogenesis, and more severe course6,7. This disorder could have a variable clinical expression which makes
difficult its identification during its initial stages. To address such variability the term of neuromyelitis optica
spectrum has been suggested6, 8.
The 1999 diagnostic criteria for NMO required fulfillment of three absolute criteria: optic neuritis, acute
myelitis, and no symptoms and/or MRI findings beyond
the optic nerves and spinal cord9. The Pediatric Multiple Sclerosis Study Group adopted the modified criteria
from 200510 excluding patients with brain lesions; however, the Study Group acknowledged that these criteria11
were also applicable to the pediatric patients8,10. In 2006,
a new revised diagnostic criteria for definite NMO were
defined due to the description of a sensitive and specific
serum antibody which was called NMO immunoglobulin G (NMO-IgG)12,13. These criteria included the occurrence of optic neuritis and transverse myelitis and at least
two of three supportive criteria: MRI demonstrating involvement of a three or more contiguous spinal cord segments, brain MRI with lesions not compatible with multiple sclerosis or NMO-IgG seropositivity11.
The introduction of the new criteria brought some
difficulties to the NMO pediatric group (also to the adult
group) due to the acceptance of white matter lesions seen
in brain MRI11.
Although spinal cord lesions are considered the landmark of NMO in children, it has been suggested that
around half of the children with the diagnosis of NMO
have neuroimaging evidence of brain lesions as well14-16.
Furthermore, several lesions located in the hypothalamus,
brainstem or diffuse cerebral white matter have been described in children with typical features of NMO14,16.
Another controversial diagnostic issue is related to the
role of the serologic findings in pediatric NMO concerning the specific serum antibody NMO-IgG. The aquaporin 4-specific (AQP4) water channel autoantibody NMOIgG is detected in 73% of adults with NMO. However,
Banwell, Tenembaun, and cols.16 reported that NMO-IgG
in pediatric patients is a sensitive marker only for relapsing NMO.
The reports of NMO in children are limited and more
complexity is added to the disease characterization. Ten
years ago, in 1999, the diagnostic criteria for NMO were
first described and ever since two other criteria have been
developed. These changes, linked to the low prevalence of
the disorder in pediatric ages, have made more difficult
the study of the true nature of NMO in children. Due to
the dearth of information regarding pediatric NMO we
aim to describe the clinical presentation as well as the
neuroimaging characterization and the presence of the
NMO immunoglobulin G antibody in a cohort of pediatric patients with NMO.
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METHOD
The patients described in this study were children seen in two different cities in Venezuela: [1] the
Neuropediatrics Service of the JM de los Rios Pediatric
Hospital, in Caracas, and [2] The University Hospital in
Maracaibo. Maracaibo and Caracas are the most populated cities in the country. All patients in Maracaibo were
examined by the principal author (Dr. Peña), and those
in Caracas by the second author (Dr. Ravelo). The children were first seen between December 2002 and December 2008. The diagnosis of inflammatory demyelination encompassing the spectrum of neuromyelitis optica
was based on clinical symptomatology, MRI and serologic analysis, which are in compliance with the most recent
pediatric NMO diagnostic criteria11, which states that for
a NMO diagnosis a child needs: optic neuritis and transverse myelitis and at least two of three supportive criteria (MRI demonstrating involvement of a three or more
contiguous spinal cord segments, brain MRI with lesions
not compatible with multiple sclerosis or NMO-IgG antibody seropositivity). Patients’ information concerning
age, symptoms in each bout, number of bouts, laboratory findings, MRI results and treatment were reviewed
for each patient.
The brain and spine MRI scans of each patient were
reviewed by radiologists who were blind to the diagnosis within the MS spectrum. Most of the scans were performed within two months from the onset of the symptoms and the criteria for the revision were: number, location, size, and enhancement characteristics of the lesions. For the spinal cord scans the spinal segment length
was also recorded.
Serum samples from all but one child were analyzed
for NMO-IgG antibody in the Mayo Clinic Neuroimmunology Laboratory. For each child, oligoclonal IgG bands
in cerebrospinal fluid were tested in the Neuroimmunology Laboratory of the Universidad Central de Venezuela. This study was usually requested after the first MRI
scan was performed. Parents and guardians filled out an
Informed Consent.
Six patients, five females and one male, were evaluated. Age at symptoms onset ranged from five to 13 years
and the median age at the time of the study was 11 years
old. They all presented three or more different bouts of a
demyelinating disorder with brain and/or vertebral MRI
confirmation. Five patients were white / non-Caucasian,
and one was Amerindian. All children were of Venezuelan origin, with no family history of any demyelinating
disorder.
RESULTS
Patients’ characteristics, clinical, laboratory and MRI
findings are exhibited in Table.
35
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Table. Clinical and demographic characteristics of the sample.
Case

1

2

3

4

5

6

Age

12

13

13

12

8

8

Gender

Female

Female

Female

Male

Female

Female

First attack

Vision loss

Vision loss,
cephalea

Vision loss,
paresthesias,
right arm
weakness

Paresthesia,
paraparesis

Vision loss

Vision loss,
paraparesis,
somnolence,
irritability

Interval between
1st and 2nd attacks

7 months

5 months

2 months

6 months

8 months

2 months

Current treatment

AZT

AZT, Prednisone

Prednisone, AZT

Prednisone

AZT, Prednisone

AZT, Prednisone

MRI/spine

C2-C5, C7-T4

C6-D8, D10-D11

C2-C6, D1-D3

C1-T5

C6-D8, D10-D11

C2-C5, D1-D10

Brain

PV

PV, CR

PV, CR, CC

PV, CR,
Cerebellum

No. of attacks

5

7

3

3

4

3

Outcome

Bilateral vision
loss, paraparesis

Bilateral vision
loss, paraparesis

Bilateral vision
loss, paraparesis

Bilateral vision
loss, paraparesis

Bilateral vision
loss, paraparesis

Bilateral vision
loss, paraparesis

NMO-IgG (y)

Pos (19)

Pos (15.2)

Pending

Neg (13)

Pos (12.5)

Pos (11)

AZT: azathioprine; PV: periventricular; CR: corona radiate; CC: corpus callosum; ON: optic neuritis.

Fig 1. MRI scans of the spinal cord in patients 2 [A] and 5 [B, C] with
NMO. [A] Longitudinally extensive irregular lesion from T4 to T9
levels. [B] Swollen cervical spinal cord with a longitudinally extensive lesion involving the central area of the cord. [C] Axial imaging
of cervical cord showing central pattern of involvement.

Optic neuritis
In three patients ON was the initial presentation followed by TM (patients 1, 2 and 5), being apart for seven,
five and eight months respectively. On the contrary, ON
followed the initial presentation of TM six months later in patient 4, and ON occurred concurrently with TM
in patients 3 and 6. All the cases exhibited bilateral ON
with severe impairment in five of them. At the last med36

Fig 2. Abnormal brain MRI in patients with NMO. [A] Patient 1: axial
T1-weighted images showing several hyperintense lesions in periventricular area. [B] Patient 5: axial T1-weighted images displaying
white matter hyperintense lesions; the saggital images show lesions in corpus callosum and pons. [C] Patient 6: axial T1-weighted images of hyperintense lesions in thalamus, corpus callosum,
upper pons, and cerebellum.

ical examination, all patients showed evidence of bilateral vision loss and crural paraparesis. Patients 1, 2, 5 and 6
had complete vision loss in both eyes, and the other two
children had partial vision recovery in both eyes.
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Transverse myelitis
As mentioned before, only in one patient the TM
was the initial presentation (patient 4); however, clinical symptoms related to TM were seen in all cases during the course of the disease, especially after the second
relapse. In addition, the involvement of more than three
spinal segments that included cervico-thoracic segments
(Fig 1) was present in all children.
Disease course
All patients presented a relapsing-remitting course,
with a median time of six months (range two to eight
months) to the second relapset, and an average number
of attacks of 4.16.
Brain involvement
Although the initial presentation of ON and the
subsequent development of TM was the main form of
the disease observed in this sample, another clinical presentations were observed, including crural paraparesis followed by ON or ON appearing concurrently with
TM. Four patients exhibited abnormalities on brain MRI
from disease onset, but only three developed symptoms
related to brain disease during the course of the disorder (patients 2, 5 and 6). Headache, vomiting and vertigo
occurred during the third clinical relapse in patient 2,
while aphasia was documented among other findings in
patient 5. Patient 6 exhibited seizures, somnolence and
irritability as part of her second clinical relapse. Table
1 shows the distribution of the lesions. Although most
of the changes were nonspecific, these three patients
displayed atypical lesions which included large confluent
cerebral or diencephalon lesions, periventricular lesions
in the temporal horns of the lateral ventricles, and juxtacortical and central white matter lesions (Fig 2). Patients
5 and 6 had the most striking brain involvement with
extensive signal abnormalities in the periventricular white
matter and corpus callosum (Fig 2). The MRIs follow
up displayed increased brain involvement and progressive brain atrophy in two patients (patient 5 and 6). It is
important to mention that none of the images reviewed,
or the recorded lesions fulfilled the Barkhof criteria
for MS17.
Serology
NMO-IgG antibody was tested in five patients, with
positive results in four of them (80%). At different stages of the disorder, five patients underwent cerebrospinal
fluid (CSF) analysis, two had pleocitosis (35 and 20 cells/
mm3), while other two had normal cell count. Oligoclonal bands were negative in all cases, and none of the patients had serologic evidence of other autoimmune antibodies or disorders.
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Treatment
All patients received high-doses of methylprednisolone for the treatment of the acute attacks. One patient
was treated with intravenous immunoglobulin for one
acute attack (patient 2). Four patients were treated with
prednisone and azathioprine simultaneously (patients 2,
3, 5 and 6).Three of the patients were initially diagnosed
as MS, and for that reason they received Interferon b1a
until the final diagnosis was achieved (patients 1, 5 and 6).
DISCUSSION
As an uncommon entity in pediatric ages, the clinical features of NMO are still being characterized. The demographic features of this sample were similar to those of
other cohorts with adults or children, most of the cases
were female and all children were from non-white populations, one of them being Amerindian6,8,17,18. Recently,
race has been considered an important demographic variable for NMO in children, with a predominance of Latin American and African ancestry6, and occurring also
more frequently in non-white racial groups16,19. Race-related findings might indicate that Northern European ancestry is not as determinant in pediatric-onset demyelinating disorders as it is in the adult NMO population8,19.
The clinical manifestations in this small sample point
toward a diverse initial presentation of NMO in Hispanic children. The optic involvement was bilateral in all patients, leading to bilateral optic atrophy. We consider this
an important finding, not only for being the most common
presentation of the disease in this sample, but also because of the ON sequelae: 60% of the children were blind
and 40% had some kind of visual impairment. It seems
then, that ON is the most impairing feature in NMO.
Spinal cord lesions evidenced by spinal MRI had been
reported as the single most useful diagnostic feature in
the NMO spectrum disorder, both in adults and children7,20. For our sample, this additional criterion was observed in the entire group. However, there are patients
with NMO who do not have the specific lesion length
characteristic of the disorder thus stressing the supportive condition of this criterion.
Four of our cases exhibited the disseminated nature
of the central white matter demyelination that extended
beyond the optic nerves and spinal cord which is another
supportive criteria according to the most recent classification11. In fact, recent studies have reported a high frequency of brain MRI abnormalities in patients who fulfill criteria for NMO14,15,21, including nonspecific lesions, atypical
and thalamic or hypothalamic lesions that could be related
to hypothalamic endocrinopathies, and also extensive cerebral white matter lesions8,22. As mentioned before, three
patients exhibited signal abnormalities in the diencephalon without apparent metabolic or endocrine findings.
37
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Symptoms related to brain disorders, which have been
reported in other pediatric series, were observed in our
sample8-16. Throughout the study, one of our patients presented headache, vomiting and vertigo, another had seizures while other had symptoms of expressive aphasia
in the course of the disorder, probably related to an extensive tumefactive white matter lesion in the left hemisphere. Moreover, in four patients there were an atypical
brain MRI since the initial relapse with extensive brain
damage on follow-up. Such evolution pattern has been
well described in NMO literature and should prompt
neuropediatricians to follow-up their NMO patients, with
brain MRI, regardless of the initial presentation.
Inclusion of the autoantibody testing in the recently
revised diagnostic criteria for NMO led to the distinction
of this disorder from MS and other autoimmune CNS diseases. This antibody, which has 73% sensitivity and 91%
specificity, has classified NMO as a brain blood barrier
channelopathy with abnormal humoral immunity activation12. It was positive in 80% of the patients in our sample.
However, 10 to 25 % of the patients clinically diagnosed
as NMO are seronegative for NMO-IgG. An important
finding for our sample was that all the patients who had
positive NMO-IgG were the same who showed brain lesions at the MRI. Published studies report that sites of
high brain aquaporin 4 expressions seem to correspond
with brain MRI abnormalities in this group of patients13,23.
According to our findings, we can conclude that demographic characterization of NMO in children is similar
to adults’, exhibiting a higher prevalence of females and
non-white populations. The characterization of this entity in children could be done by using the new 2006 criteria, with an emphasis on the possibility of brain lesions
or symptoms of brain involvement that do not meet MS
criteria. The presence of ON and TM as required criteria, in addition to the three supportive criteria in pediatric samples, was also evident in this study.
This study highlights the association of seropositivity of NMO-IgG and the presence of brain lesions in
the NMO pediatric group. The heterogeneity of symptoms and neuroimaging characterization suggest that the
term “neuromyelitis optica” should be applied to a broader clinical syndrome in pediatric patients.

38

Arq Neuropsiquiatr 2011;69(1)

1.
2.
3.
4.
5.
6.
7.
8.
9.

10.

11.

12.

13.

14.
15.
16.

17.

18.

19.
20.

21.

22.
23.

REFERENCES

Galetta SL, Bennett J. Neuromyelitis optica is a variant of multiple sclerosis.
Arch Neurol 2007;64:901-903.
Frohman EM, Kerr D. Is neuromyelitis optica distinct from multiple sclerosis? something for “lumpers” and “splitters.” Arch Neurol 2007;64:903-905.
Roach ES. Is neuromyelitis optica a distinct entity? Arch Neurol 2007;64:906.
Weinshenker BG. Neuromyelitis optica is distinct from multiple sclerosis.
Arch Neurol 2007;64:899-901.
Lana-Peixoto MA. Devic’s neuromyelitis optica: a critical review. Arq Neuropsiquiatr 2008;66:120-138.
Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG,
The spectrum of neuromyelitis optica. Lancet Neurol 2007;6:805-815.
Pittock SJ. Neuromyelitis optica: a new perspective. Semin Neurol 2008;28:
95-104.
Lotze TE, Northrop JL, Hutton GJ, Ross B, Schiffman JS. Spectrum of pediatric neuromyelitis optica. Pediatrics 2008;122:1039-1047.
Wingerchuk DM, Hogancamp WF, O’Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic’s syndrome). Neurology 1999;53:
1107-1114.
Krupp LB, Banwell B, Tenembaum S. Consensus definitions proposed for
for pediatric multiple sclerosis and related disorders. Neurology 2007;68
(Suppl 2):S7-S12.
Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker DM.
Revised diagnostic criteria for neuromyelitis optica. Neurology 2006;66:
1485-1489.
Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004;
364:2106-2112.
Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optico-spinal multiple sclerosis binds to the aquaporine-4 water channel. J
Exp Med 2005;202:473-477.
Pittock SJ, Lennon VA, Krecke K, et al. Brain abnormalities in neuromyelitis
optica. Arch Neurol 2006;63:390-396.
Poppe AY, Lapierre Y, Melancon D, et al. Neuromyelitis óptica with hypothalamic involvement. Mult Scler 2005;11:617-621.
Banwell B, Tenembaum S, Lennon VA, et al. Neuromyelitis optica-IgG in
childhood inflammatory demyelinating CNS disorders. Neurology 2008;70:
344-352.
Peña J, Montiel-Nava C, Ravelo ME, Gonzalez S, Mora La Cruz E. Multiple
sclerosis in children: clarifying its place among the demyelinating spectrum. Invest Clin 2006;47:413-425.
Ghezzi A, Bergamaschi R, Martinelli V, et al. Clinical characteristics,
course and prognosis of relapsing Devic’s neuromyelitis optica. J Neurol
2004;251:47-52.
Ness JM, Chabas D, Sadovnick AD, et al. Clinical features of children and
adolescents with multiple sclerosis. Neurology 2007;68(Suppl 2):S37-S45.
Papais-Alvarenga RM, Miranda Santos CM, Puccioni-Sohler M, et al. Optic
neuromyelitis síndrome in Brazilian patients. J Neurol Neurosurg Psychiatr 2002;73:429-435.
Misu T, Fujihara K, Nakashima I, Sato S, Itoyama Y. Intractable hiccup and
nausea with periaqueductal lesions in neuromyelitis optica. Neurology
2005; 65:1479-1482.
Nakamura M, Endo M, Murakami K, et al. An autopsied case of neuromyelitis optic with a large cavitary cerebral lesion. Mult Scler 2005;11:735-738.
Lucchinetti CF, Mandler RN, McGavern Det al. A role for humoral mechanisms in the pathogenesis of Devic’s neuromyelitis optica. Brain 2002;125:
1450-1461.

